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Objective: To compare the bioavailability of single dose ibuprofen 200mg and
pseudoephedrine hydrochloride 30mg administered alone or in combination as an oral
suspension.
Methods: This was a single-center, randomized, single-dose, open-label, 3-period,
crossover study. After an overnight fast (≥10 h), 18 healthy male subjects received either
ibuprofen 200mg (reference-A), pseudoephedrine 30mg (reference-B) or the combination
(test-C) as a suspension, on 3 separate visits, with blood sampling up to 36-h post-dose.
The primary pharmacokinetic parameters, maximum plasma concentration (Cmax) and area
under the plasma concentration–time curve (AUC) from time zero to last measurable
concentration (AUC0 t) and extrapolated to infinity (AUC− 0 ) were compared by an−∞
analysis of variance using log-transformed data. Bioequivalence was concluded if the 90%
confidence intervals (CIs) of the adjusted geometric mean (gMean) ratios for Cmax and
AUC were within the predetermined range of 80–125%, in accordance with regulatory
requirements.
Results: For the test formulation, the ibuprofen gMean Cmax was 17.0µg/mL (vs.
18.1µg/mL for reference-A), AUC0 t was 57.1 (vs. 60.0µg·h/mL), and AUC− 0 was−∞
59.9µg·h/mL (vs. 63.1µg·h/mL). The 90% CIs for the ratio (test/reference-A) were
81.0–108.1% for Cmax, 91.5–98.4% for AUC0 t and 91.6–97.9% for AUC0 . For− −∞
pseudoephedrine, the gMean Cmax for the test formulation was 97.2 ng/mL (vs. 98.5 ng/mL
for reference-B), AUC0 t was 878.4 (vs. 842.8 ng·h/mL) and AUC0 was 907.8 ng− −∞ ·h/mL
(vs. 868.3 ng·h/mL). The 90% CIs for the ratio (test/reference-B) were 92.4–106.9% for
Cmax, 97.7–111.0% for AUC0 and 97.9–111.3% for AUC . All treatments were well−t 0−∞
tolerated.
Conclusion: This oral suspension containing ibuprofen and pseudoephedrine combined
in a new formulation met the regulatory criterion for bioequivalence compared with oral
suspensions containing the individual components.
Keywords: bioequivalence, ibuprofen, NSAIDs, pseudoephedrine, pharmacokinetics
INTRODUCTION
Ibuprofen and pseudoephedrine are commonly used for symp-
tomatic management of the common cold, sinusitis and
influenza. The benefit from these agents is due to a combi-
nation of analgesic, antipyretic and anti-inflammatory effects
of ibuprofen and decongestant effects of pseudoephedrine
(Anonymous, 1999b; Rainsford, 2013). Both agents are rapidly
absorbed after oral administration, with peak plasma concen-
trations (Cmax) achieved within 1–2 h for ibuprofen and after
1–3 h for pseudoephedrine (Davies, 1998; Anonymous, 1999a,b).
Taken together, it is likely that there would be potential for
improved symptomatic relief with a combination product, sub-
ject to demonstration of bioequivalence. Various formulations of
combined ibuprofen and pseudoephedrine, including oral tablets,
slow-release capsules and liqui-gel suspensions have been studied
and approved for clinical use in adults and children. The aim of
this study was to compare the pharmacokinetics of an oral sus-
pension containing ibuprofen and pseudoephedrine combined in
a new formulation vs. oral suspensions containing the individual
components at the same doses.
SUBJECTS AND METHODS
This was a single-center (Lambda Therapeutic Research Ltd,
Ahmedabad, India), randomized, single-dose, open-label, 3-
treatment, 3-period, 6-sequence, crossover trial conducted in
healthy volunteers between June and July 2003. The study
protocol was approved by an independent ethics commit-
tee, and was conducted in accordance with local regulations
and the Declaration of Helsinki and Good Clinical Practice.
Written informed consent was obtained from all subjects before
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performing any trial-related activities. The study design was in
accordance with the European Medicine Agency note for guid-
ance on the investigation of bioavailability and bioequivalence of
fixed combination products (European Medicines Agency, 2002)
and US Food and Drug Administration guidance for industry on
the bioavailability and bioequivalence of oral drugs (US Food and
Drug Administration, 2003).
SUBJECTS
Healthy male subjects aged 18–55 years with a body mass index
(BMI) of 18–25 kg/m2 were considered for the study. Subjects had
no significant disease (gastrointestinal, hepatic, renal, respiratory,
cardiovascular, metabolic, skin, immunological, or hormonal),
clinically significant medical history, or abnormal ECG, vital
signs or laboratory values at screening 21 days before dosing.
Additional exclusion criteria included allergy to ibuprofen, pseu-
doephedrine, or other non-steroidal anti-inflammatory drugs
(NSAIDs), history of asthma, nasal polyp or NSAID-induced
urticaria or drug or alcohol abuse; subjects who smoked >10
cigarettes per day or could not abstain during the study, who
participated in another trial within 90 days, or used any other
medication within 14 days of enrolment were also excluded.
Subjects were tested for drug and alcohol consumption prior to
each study period.
STUDY DESIGN AND TREATMENTS
The study comprised a screening period followed by 3 treatment
periods, each separated by a 12-day washout period. Subjects were
randomly assigned using a computer-generated list to receive
one of 6 possible treatment sequences for single dose ibuprofen
(200mg suspension, 100 mg/5mL, reference A), single dose
pseudoephedrine hydrochloride (30mg suspension, 15mg/5mL,
reference B) or the combination of ibuprofen 200mg and pseu-
doephedrine 30mg (suspension, test C) (Figure 1). All treat-
ments were manufactured by Orbis Consumer Products Limited,
Middlesex, United Kingdom.
Subjects attended the study center on the evening before dos-
ing. After fasting overnight (≥10 h), subjects were dosed orally
(10mL suspension with 240mL of water) in the sitting posi-
tion by study personnel using a syringe. The syringe was then
rinsed with water and administered again with any remaining
water. Administration was confirmed by a mouth-check. Water
was allowed ad libitum except 1 h before and 2 h after dosing.
Subjects were seated or in ambulatory posture for 3 h post-dose
and fasted for 4 h after dosing. During each period subjects
remained in the study center until blood samples had been taken
20 h (ibuprofen alone) and 36 h (pseudoephedrine alone and
ibuprofen-pseudoephedrine) after dosing. Xanthine-containing
food or beverages, alcohol, extreme physical activity, cigarettes
and tobacco products were not permitted 48 h before and during
post-dose blood sampling.
PHARMACOKINETIC EVALUATION
Venous blood samples (6mL for each reference product, 8mL
for the test product) for measurement of plasma concentrations
of ibuprofen and pseudoephedrine were collected in heparinized
vacutainers via an indwelling cannula during each study period
before and at 10, 20, 40, 50, and 60min of the first hour, and
thereafter every 20min for up to 3 h, and 3.5, 4, 6, 8, 10, and
12 h after dosing. Additional samples were collected at 16, 24, 30,
FIGURE 1 | Study design.
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and 36 h after dosing with treatments B and C. Samples were cen-
trifuged for 15min at 10◦C (2960 rpm) and plasma aliquots were
taken and frozen (−20◦C then −60◦C) until analysis.
Plasma concentrations of ibuprofen and pseudoephedrine
were analyzed separately using liquid chromatography mass
spectrometry procedures, which were fully validated and devel-
oped from methods previously used by Lambda Therapeutic
Research Ltd, Ahmedabad, India (Lambda, Data on File). Briefly,
ibuprofen plasma concentrations were measured following pro-
tein precipitation extraction (internal standard diclofenac) by
high pressure liquid chromatography (HPLC) using a Kromasil®
C18 250 × 4.6mm, 5µm column (mobile phase 28% acetoni-
trile and 72% buffer pH 6.8). The limit of quantification was
0.730µg/mL. Pseudoephedrine plasma concentrations were ana-
lyzed following liquid-liquid extraction (carbamazepine as the
internal standard) by liquid chromatography-mass spectrom-
etry (LC-MS/MS) analysis using a 50 × 4.6mm Chromolith®
SpeedROD RP-18e column (mobile phase 90% methanol and
10% 2mM ammonium acetate buffer, pH 3.5). The limit of quan-
tification was 2.053 ng/mL. Assay performance was assessed by
back-calculation of calibration standards, tabulation of the stan-
dard curve fit function parameters and measurement of quality
control samples. Validation data documented adequate accu-
racy, precision and specificity of the liquid chromatography mass
spectrometry assays employed for the study.
SAFETY EVALUATION
Clinical examination findings and vital signs (pulse, blood pres-
sure) were reported on admission and before discharge from the
study center in all 3 study periods. Vital signs were measured 4, 8,
and 12 h (for all treatments) and additionally 24, 30, and 36 h (for
treatments B and C) after dosing. Subjects were questioned for
well-being at the time of clinical assessments. Adverse events were
collected during each study period with severity (mild, moderate
or severe) and investigator assessment of the relationship to the
study medication (definite, possible, doubtful, or none).
PHARMACOKINETIC ANALYSES
The primary variables were the area under the plasma
concentration-time curve from time 0 to the last quantifiable
data point (AUC0−t), from time zero extrapolated to infinity
(AUC0−∞) and Cmax. Time of maximum exposure (tmax) was
a secondary variable. Non-compartmental analysis of plasma
concentration-time data was performed using WinNonlin®
Professional software (Version 4.0.1, Pharsight Corporation,
Cary, NC, USA). All values below the limit of quantification were
considered as zero for pharmacokinetic analysis.
STATISTICAL ANALYSES
Subjects were simultaneously enrolled in the study so as to ensure
that at least 18 subjects were dosed at the beginning of the study.
This number of subjects was considered appropriate for this type
of study. In case of drop-outs, samples from subjects who com-
pleted at least 2 periods of the study were analyzed, provided they
had completed treatment with the test product.
Statistical analyses were performed using PROC MIXED
(SAS®, version 8.2, SAS Institute Inc., Cary, NC, USA). AUC0−∞,
AUC0−t, and Cmax data for ibuprofen and pseudoephedrine
were log-transformed and compared between treatment groups
using an analysis of variance (ANOVA) model with sequence,
subjects within sequences, period and treatment as sources of
variation. The least square means and 90% confidence intervals
(CI) were calculated and then back-transformed to the origi-
nal scale to provide the point estimator and interval estimates
for the geometric mean (gMean) of intra-subject test/reference
ratio. In accordance with regulatory requirements (European
Medicines Agency, 2002; US Food and Drug Administration,
2003), bioequivalence was concluded if the 90% CIs were within
the range 80–125%. For all other parameters, descriptive statis-
tics were presented. Tmax was compared using the Wilcoxon
signed rank test. Intra-subject variability and power to detect a
20% mean difference between formulations were calculated for
Table 1 | Baseline characteristics of the randomized male study
population (n = 18).
Characteristic
Age [years] 25.9±6.2 (18−39)
Weight [kg] 57.8±5.2
BMI [kg/m2] 20.6±1.9
Data shown as mean ± standard deviation (range).
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FIGURE 2 | Geometric mean plasma concentration vs. time curves for
(A) ibuprofen from an ibuprofen/pseudoephedrine combination vs.
ibuprofen alone, (B) pseudoephedrine from a pseudoephedrine/
ibuprofen combination vs. pseudoephedrine alone.
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log-transformed pharmacokinetic parameters using root mean
square error computed by PROCMIXED.
RESULTS
PARTICIPANTS
Nineteen healthy Indian male subjects were enrolled and 18 sub-
jects aged 18–39 years were randomized; one subject withdrew
before dosing and was subsequently replaced. The participant
demographic characteristics are summarized in Table 1. Fifteen
subjects completed all 3 dosing periods. Three subjects discon-
tinued the study due to an adverse event, protocol violation,
or withdrawal for personal reasons; 2 of these subjects received
both pseudoephedrine (reference B) and the combination (test
C) before withdrawal and were therefore included in pharmacoki-
netic analyses for these treatments.
PHARMACOKINETIC PROFILES
The ibuprofen and pseudoephedrine plasma concentration-time
profiles are shown in Figure 2 and pharmacokinetic parameters
are summarized in Tables 2, 3.
Ibuprofen
Ibuprofen was rapidly absorbed, with a median tmax of 50min
(either alone or in combination, p = 0.67) (Table 2). The plasma
concentration-time curves of ibuprofen (with or without pseu-
doephedrine) showed a parallel decline in distribution and elim-
ination phases (Figure 2A). The gMean values of Cmax, AUC0−t
and AUC0−∞ for ibuprofen were similar when given alone or in
combination with low interindividual variation (CV ranged from
14.3 to 27.9%). Bioequivalence was demonstrated as the 90% CIs
of the ratios of point estimates (test/reference) for Cmax, AUC0−t,
and AUC0−∞ were within the range of 80–125%.
Pseudoephedrine
Pseudoephedrine was rapidly absorbed, with a median tmax of
100 and 120min for the combination and when given alone,
respectively (p = 0.92) (Table 3). The plasma concentration-
time curves of pseudoephedrine (with or without ibuprofen)
showed a similar parallel decline in distribution and elimina-
tion phases (Figure 2B). The gMean values of Cmax, AUC0−t, and
AUC0−∞ for pseudoephedrine were similar when given alone or
Table 2 | Pharmacokinetic parameters of ibuprofen 200 mg, either alone (reference A), or in combination with pseudoephedrine 30mg (test, C)
(n = 15).
Parameter and unit Ibuprofen (n = 15)a Adjusted gMean ratios (90% CI) (%)c Intra subject gCV [%]c
Alone (Reference, A) +pseudoephedrine (Test, C)
AUC0−t[µg·h/mL] 60.0 (14.3) 57.1 (19.0) 94.9 (91.5–98.4) 5.6
AUC0−∞ [µg·h/mL] 63.1 (14.6) 59.9 (18.1) 94.7 (91.6–97.9) 5.1
Cmax[µg/mL] 18.1 (21.9) 17.0 (27.9) 93.6 (81.0–108.1) 22.3
tmax [h]b 0.83 (0.67–2.67) 0.83 (0.67–3.50)
t½[h] 1.96 (15.4) 2.00 (14.6)
aResults are presented as geometric mean (CV%) unless stated.
bThese values are expressed as median (range).
cLog-transformed data, ratio of least-square geometric means (test/reference) based on ANOVA model.
AUC0−∞area under the concentration-time curve from zero time to infinity, AUC0−t area under the plasma concentration-time curve from zero time to time of the last
quantifiable drug plasma concentration, Cmax maximum observed plasma concentration, CI confidence interval, CV coefficient of variation (%), gMean geometric
mean, tmax time to reach Cmax , t½ terminal half-life.
Table 3 | Pharmacokinetic parameters of pseudoephedrine 30mg either alone (Reference A) or in combination with ibuprofen 200mg (Test, C)
(n = 17).
Parameter and unit Pseudoephedrine (n = 17)a Adjusted gMean ratios (90% CI) (%)c Intra subject gCV [%]c
Alone (Reference, B) +ibuprofen (Test, C)
AUC0−t [ng·h/mL] 842.8 (34.5) 878.4 (267) 104.1 (97.7–111.0) 10.6
AUC0−∞ [ng·h/mL] 868.3 (34.2) 907.8 (25.9) 104.4 (97.9–111.3) 10.6
Cmax [ng/mL] 98.5 (21.1) 97.2 (21.4) 99.4 (92.4–106.9) 12.0
tmax [h]b 1.67 (0.67–3.0) 2.00 (0.83–3.0)
t½ [h] 4.7 (18.4) 4.9 (16.0)
aResults are presented as geometric mean (CV%) unless stated.
bThese values are expressed as median (range).
cLog-transformed data, ratio of least-square geometric means (test/reference) based on ANOVA model.
AUC0−∞ area under the concentration-time curve from zero time to infinity, AUC0−t area under the plasma concentration-time curve from zero time to time of
the last quantifiable drug plasma concentration, Cmax maximum observed plasma concentration, CI confidence interval, CV coefficient of variation (%), gMean
geometric mean, tmax time to reach Cmax , t½ terminal half-life.
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in combination with low interindividual variation (CV ranged
from 21.1 to 34.5%). Bioequivalence was demonstrated as the
90% CIs of the point estimates (test/reference) for Cmax, AUC0−t,
and AUC0−∞) were in the range 80–125%.
SAFETY RESULTS
A total of 14 treatment-emergent adverse events were reported by
9 subjects (3 for the test formulation, 6 for ibuprofen alone and
5 for pseudoephedrine alone). All adverse events were mild and
resolved spontaneously. Two events were considered as possibly
related to the test medication (test C). One subject reported fore-
arm itching which was considered definitely related; the event was
also reported with pseudoephedrine alone and was also consid-
ered possibly related to the study drug. Another subject reported
heartburn which was considered as possibly related to the study
medication. In addition, itching and generalized body ache were
reported as possibly related to reference A (ibuprofen alone).
There were no clinically relevant changes in vital signs, ECGs or
laboratory findings.
DISCUSSION
The present study confirmed that the rate (Cmax and tmax) and
extent (AUC) of absorption of ibuprofen or pseudoephedrine
from a suspension formulation were similar when administered
as single doses of the individual components and when adminis-
tered in combination in healthy volunteers. The 90% CIs for the
treatment ratios (combination/individual treatments) for Cmax,
AUC0−t, and AUC0−∞ of ibuprofen and pseudoephedrine were
within the range of 80–125% and therefore satisfied regulatory
criteria for bioequivalence (European Medicines Agency, 2002;
US Food and Drug Administration, 2003).
For both oral ibuprofen 200mg and pseudoephedrine
hydrochloride 30mg, AUC0−t and Cmax in this study (see
Tables 1, 2) were similar to those reported for a film-coated
tablet (58.6µg·h/mL and 14.8µg/mL, respectively for ibuprofen;
1080 ng·h/mL and 139 ng/mL for pseudoephedrine) (Boehringer
Ingelheim, 2011). Further studies show that multiple dose admin-
istration of combined ibuprofen and pseudoephedrine, either as
modified-release capsules in healthy adult males or as an oral
suspension in children, has a similar pharmacokinetic profile as
compared with single-ingredient formulations (Stillings et al.,
2003; Gelotte et al., 2010).
Single doses of ibuprofen and pseudoephedrine were well-
tolerated when given alone and in the combination treatment to
healthy male volunteers. Itching reported for one patient treated
with pseudoephedrine alone or in combination with ibupro-
fen was consistent with the established tolerability profile of
pseudoephedrine (Anonymous, 1999b).
In summary, this ibuprofen-pseudoephedrine combination
formulation met the regulatory criterion for pharmacokinetic
bioequivalence compared with concurrent administration of the
individual components.
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